Table: Anges -Q1 group results
Apr 27 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2020 Mar 31, 2019 Dec 31, 2020
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 5 mln 75 mln
(-92.4 pct) (+2.4 pct)
Operating loss 974 mln loss 918 mln
Recurring loss 922 mln loss 938 mln
Net loss 919 mln loss 1.18
EPS loss 8.56 yen loss 11.92 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001